Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide to Prevent Post-Op CSF Leak
NCT02902133Phase 2Withdrawn
- Sponsor
- University of Miami
- Start
- Sep 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of acetazolamide in cerebrospinal fluid leak, sponsored by University of Miami. Primary endpoint: Incidence of Cerebrospinal Fluid Leakage at 30 days. Planned start Sep 2016; status: withdrawn.
02
Drugs
acetazolamide
03
Conditions
cerebrospinal fluid leak
Beyond the preview
Go deeper on NCT02902133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902133.